MPI Pyrophosphate Kit Kit for the Preparation of Technetium Tc 99m Pyrophosphate DIAGNOSTIC-FOR INTRAVENOUS USE
|
|
- Candace Green
- 5 years ago
- Views:
Transcription
1 MPI Pyrophosphate Kit Kit for the Preparation of Technetium Tc 99m Pyrophosphate DIAGNOSTIC-FOR INTRAVENOUS USE DESCRIPTION: Each reaction vial contains 40 mg sodium pyrophosphate (equivalent to 23.9 mg anhydrous sodium pyrophosphate) and 0.4 mg stannous fluoride (minimum) and 0.9 mg total tin (maximum) as stannous fluoride; the product does not contain a preservative. The ph of the product is adjusted with sodium hydroxide or hydrochloric acid prior to lyophilization. At the time of manufacture, the air in the vial is replaced with a nitrogen gas atmosphere. The ph of the reconstituted product is 5.5 to 6.9. When sterile, non-pyrogenic sodium pertechnetate Tc 99m solution is added to the vial, a diagnostic agent, technetium Tc 99m Pyrophosphate, is formed for intravenous administration; the structure of this radiolabeled complex is unknown. The product as supplied is sterile and nonpyrogenic. PHYSICAL CHARACTERISTICS: Technetium Tc 99m decays by isometric transition with a physical half-life of 6.02 hours. The principal photon that is useful for detection and imaging studies is shown intable 1. Table 1. Principal Radiation Emission Data 1 Radiation Mean %/Disintegration Mean Energy (kev) Gamma 'Kocher, David C., "Radioactive Decay Data Tables," DOE/ TIC (1981). EXTERNAL RADIATION: The specific gamma ray constant for Tc 99m is 0.78 R/hour-millicurie at 1 cm. The first half-value layer is cm of lead (Pb). A range of values for the relative attenuation of the radiation emitted by this radionuclide that results from interposition of various thicknesses of Pb is shown in Table 2. To facilitate control of the radiation exposure from millicurie amounts of this radionuclide, the use of a 0.25 cm thickness of Pb will attenuate the radiation emitted by a factor of 1,000. Table 2. Radiation Attenuation of Lead (Pb) Shielding Shield Thickness (Pb)cm Coefficient of Attennuation To correct for physical decay of this radionuclide the fractions that remain at selected intervals after the time of calibration are shown in Table 3. TABLE 3 Physical Decay Chart: Tc 99m half-life 6 02 hours Hours 0 * Fraction Remaining Calibration Time Hours Fraction Remaining CLINICAL PHARMACOLOGY: Bone and Cardiac Imaging: Following intravenous administration of the technetium Tc99m pyrophosphate, skeletal uptake occurs as a function of blood flow to bone and bone efficiency in extracting the complex. Bone mineral crystals are generally considered to be hydroxyapatite, and the complex appears to have an affinity for the hydroxyapatite crystals in bone. It is theorized that the
2 complex also reacts with the mitochondrial calcium crystals, produced within infarcted myocardial cells which are believed to be hydroxyapatite; this phenomenon usually does not persist beyond six days after the occurrence of an infarction. Clearance of the radioactivity from the blood is quite rapid with skeletal uptake and urinary excretion being the principal mechanisms of clearance. At two hours following intravenous injection, approximately 55 percent of the injected dose has localized in bone; at four hours approximately 10 percent of the dose remains in the vascular system, decreasing to about 7 percent at 24 hours. The average urinary excretion was observed to be about 38 percent of the administered dose after eight hours increasing to an average of about 44 percent at 24 hours. A minimum amount of uptake has been observed in soft-tissue organs, most notably the kidneys. Blood Pool Imaging: The in vivo tagging of MPI Pyrophosphate Kit results in the radiolabelling of red blood cells. Approximately 76 percent of the injected activity remains in the blood pool between 30 and 60 minutes after injection of sodium pertechnetate Tc 99m, thereby permitting excellent images of the cardiac chambers. Maximum blood radioactivity levels occur in about 30 minutes; the initial biological half-life is approximately 18 hours. There is virtually no biological elimination of the agent after approximately six hours. INDICATIONS AND USAGE: Bone Imaging: MP! Pyrophosphate Kit (Kit for the Preparation of Technetium Tc 99m Pyrophosphate) may be used as a bone imaging agent to delineate areas of altered osteogenesis. Cardiac Imaging: MPI Pyrophosphate Kit is a cardiac imaging agent used as an adjunct in the diagnosis of acute myocardial infarction. The infarction is best visualized one to six days after onset of symptoms. False-negative images can occur if imaging is done too early in the evolutionary phase of the infarct or too late in the resolution phase. The incidence of false-positives may range from 5 to 9 percent and of false-negatives from 6 to 9 percent but may vary even more depending on selection criteria of patient populations. Blood Pool Imaging: MPI Pyrophosphate Kit is also a blood pool imaging agent which may be used for gated cardiac blood pool imaging and for the detection of sites of gastrointestinal bleeding. When administered intravenously 15 to 60 minutes prior to intravenous administration of sodium pertechneetatetc99m, approximately 75% of the injected activity remains in the blood pool. CONTRAINDICATIONS: None known. WARNINGS: Preliminary reports indicate impairment of brain scans using sodium pertechnetate Tc 99m injection which have been preceded by a bone scan using an agent containing stannous ions. The impairment may result in false-positive or false-negative brain scans. It is recommended, where feasible, that brain scans precede bone imaging procedures. Alternatively, a brain-imaging agent such as technetium Tc 99m pentetate may be employed. PRECAUTIONS: General: The lyophilized contents of the MPI Pyrophosphate Kit reaction vial are to be administered to the patient only as an intravenous solution (see PROCEDURES FOR RECONSTITUTION OF MPI PYROPHOSPHATE KIT). Any sodium pertechnetate Tc 99m solution which contains an oxidizing agent is not suitable for use with MPI Pyrophosphate Kit (Kit for the Preparation of Technetium Tc 99m Pyrophosphate). When reconstituted with sodium pertechnetate Tc 99m, MPI Pyrophosphate Kit must be used within 6 hours. When reconstituted with Sodium Chloride Injection USP for blood pool imaging, use the solution within 30 minutes. The imaging of gastrointestinal bleeding is dependent on such factors as the region of imaging, rate and volume of the bleed, efficacy of labeling of the red blood cells and timeliness of imaging. Due to these factors, images should be taken sequentially over a period of time until a positive image is obtained or clinical conditions warrant the discontinuance of the procedure. The period of time for collecting the images may range up to thirty-six hours. Technetium Tc 99m pyrophosphate as well as other radioactive drugs must be handled with care, and appropriate safety measures should be used to minimize radiation exposure to the patient and occupational workers consistent with proper patient management. Radiopharmaceuticals should be used only by physicians who are qualified by training and experience In the safe use and handling of radionuclides and whose experience and training have bean approved by the appropriate government agency authorized to license the use of radionuclides. Bone Imaging: Both prior to and following administration of the technetium Tc 99m pyrophosphate, the patient should be encouraged to drink fluids and to void as often as possible thereafter to minimize radiation exposure to the bladder and background interference during Imaging. Cardiac Imaging: The patient's cardiac condition should be stable before beginning the cardiac imaging procedure. If not contraindicated by the patient s cardiac status, patients should be encouraged to drink fluids and to void as often as possible in order to reduce unnecessary radiation exposure to the bladder. Interference from chest wall lesions such as breast tumors and healing rib fractures can be minimized by employing the three recommended projections (see DOSAGE AND ADMINISTRATION). False-positive and false-negative myocardial scans may occur, therefore, the diagnosis of acute myocardial infarction depends on the overall assessment of laboratory and clinical findings.
3 Blood Pool Imaging: The reconstituted agent should be Injected by direct venipuncture. Heparinized catheter systems should be avoided, as interference with red blood cell tagging will result. Carcinogenesis, Mutagenesis, Impairment of Fertility: No long-term animal studies have been performed to determine any carcinogenic potential or impairment of fertility in males or females. Teratogenic Effects: Pregnancy Category C: Animal reproduction studies have not been conducted with technetium Tc 99m pyrophosphate. It is also not known whether technetium Tc 99m pyrophosphate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Technetium Tc 99m pyrophosphate should be administered to a pregnant woman only If clearly needed. Ideally, examinations using radiopharmaceuticals, especially those elective in nature, in women of childbearing capability should be performed during the first few (approximately 10) days following the onset of menses. Nursing Mothers: Caution should be exercised when technetium Tc 99m pyrophosphate is administered to a nursing woman. Technetium Tc 99m is excreted in human milk during lactation; therefore, formula-feedings should be substituted for breastfeedings. Pediatric Use: Safety and effectiveness in children have not been established. ADVERSE REACTIONS: Several adverse reactions due to technetium Tc 99m pyrophosphate have been reported. These were usually hypersensitivity reactions characterized by itching, various skin rashes, hypotension, fever, chills, nausea, vomiting and dizziness. DOSAGEAND ADMINISTRATION: The patient dose should be measured by a suitable radioactivity calibration system immediately prior to administration. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Intravenous doses for an average adult (70 kg) are as follows: Bone Imaging: The suggested dose is 370 to 555MBq (10 to 15 mci). Following reconstitution, technetium Tc 99m pyrophosphate is injected intravenously over a 10-to 20-second period. Imaging may be started at one hour after administration; however, for optimal results bone imaging should be performed two to four hours following administration. Cardiac Imaging: The suggested dose is 370 to 555 MBq (10 to 15 mci) administered intravenously over 10 to 20 seconds and within 24 hours to six days after the onset of symptoms suggestive of acute myocardial infarctlon. Imaging is recommended at 45 to 60 minutes post inject ion. It is suggested that scans be obtained in at least three projections (e.g., anterior, lateral, and left anterior oblique). Blood Pool Imaging: The suggested dose is 41 mg (contents of one reaction vial) of MPI Pyrophosphate Kit (see PROCEDURE FOR RECONSTITUTION) administered intravenously, followed 15 to 60 minutes later by the intravenous administration of 740 MBq (20 mci) of sodium pertechnetate Tc99m. Administration should be made by direct venipuncture and not by heparinized catheter systems. Cardiac pool Imaging should be initialed 15 to 30 minutes after the administration of sodium pertechnetatetc 99m. RADIATION DOSIMETRY: The effective half-life was assumed to be equal to the physical half-life for all calculated values. The estimated absorbed radiation doses to an average adult (70 kg) from an intravenous injection are shown in Tables 4 and 5. Table 4. Estimated Absorbed Radiation Dose Bone and Cardiac Imaging Technetium Tc 99m Sodium Pyrophosphate Target Organ mgy/555 MBq rads/15 mci Total Body Kidenys Bone Marrow Skeleton * Bladder Wall 2-hr. void hr. void Ovaries 2-hr. void hr. void Testes 2-hr. void hr. void If patient voids frequently after radiopharmacueitcal is administered, this dose will be reduced slightly. * Dose at point of highest uptake may be a factor of 10 higher.
4 Table 5. Estimated Absorbed Radiation Dose Blood Pool Imaging * Sodium Pertechnetate Tc 99m 30 min. Post Injection with Pyrophosphate Target Organ mgy/740 MBq rads/20 mci Total Body Spleen Bladder Wall Testes Ovaries Blood * Assume 75% of the Sodium PertechnetateTc 99m labels red blood cells and the other 25% remains as pertechnetate. + if 25% excreted with 1 hour T b. Method of Calculation: MIRD Dose Estimate Report No. 8 J Nucl Med 17:74-77, HOW SUPPLIED: MPI Pyrophosphate Kit (Kit for the Preparation of Technetium Tc 99m Pyrophosphate) is supplied in a kit containing 10 reaction vials (5 ml size), 10 pressure-sensitive labels, and 1 package insert. STORAGE: Store the MPI Pyrophosphate Kit (Kit for the Preparation of Technetium Tc 99m Pyrophosphate) at 2º to 8 C. The reconstituted preparation should be refrigerated since the product does not contain a preservative. When reconstituted with sodium pertechnetate Tc 99m, MPI Pyrophosphate Kit must be used within 6 hours. When reconstituted with Sodium Chloride Injection USP for blood pool imaging, use the solution within 30 minutes. PROCEDURES FOR RECONSTITUTI0N OF MPI PYROPHOSPHATE KIT: Procedural Precautions:: The contents of the MPI Pyrophosphate Kit reaction vial are sterile and nonpyrogenic. Aseptic procedures should be used during reconstitution of MPI Pyrophosphate Kit and the withdrawal of doses for intravenous administration. The introduction of air in to the vial during the reconstitution step should be avoided. The MPI Technetium Tc 99m Generator may be used as the source of sodium pertechnetate Tc99m solution; other sources which have been shown by the user to be compatible with the ingredients of MPI Pyrophosphate Kit (Kit for the Preparation of Technetium Tc99m Pyrophosphate) may also be used. Reconstitutlon: Bone and Cardiaic Imaging: Technetium Tc 99m Pyrophosphate must be used within 6 hours. 1. Waterproof gloves should be worn during the preparation procedure. 2. Allow the contents of the reaction vial to come to room temperature. 3. Place reaction vial in an appropriate lead shield with a fitted cover. * 4. Swab the rubber closure of the reaction vial with a germicide. 5. Using a shielded syringe, slowly inject 2 to 4 ml [up to 2775 MBq (75 mci)] of sterile sodium pertechnetate Tc 99m solution into the reaction vial. In determining the amount of technetium Tc 99m radioactivity to be used, the labeling efficiency, number of patients, administered radioactive dose and radioactive decay must be taken into account. NOTE: If sodium pertechnetate Tc 99m solution must be diluted for use with MPI Pyrophosphate Kit (Kit for the Preparation of Technetium Tc 99m Pyrophosphate), only Sodium Chloride Injection USP (without preservatives) should be used. 6. Secure the lead shield cover. Shake the vial gently to bring the lyophilized material into solution. 7. Record the time and date ol preparation and the radioconcentration and volume of the solution on the pressure-sensitive label. 8. Affix the pressure-sensitive label to the shield. 9. Using proper shielding, examine vial contents. If the solution is not clear and free of particulate matter and discoloration on visual inspection, it should not be used. 10. Maintain adequate shielding of the radioactive preparation including the use of appropriate shielded syringes. 11. Radioassay of technetium Tc 99m pyrophosphate may be accomplished conveniently by using an ionization chamber-type dose calibrator. Blood Pool Imaging: When reconstituted with Sodium Chloride Injection USP, MPI Pyrophosphate Kit should be used within 30 minutes. 1. Allow the contents of the reaction vial to come to room temperature. Swab the top of the rubber closure with a germicide. 2. Slowly inject 2 to 5 ml Sodium Chloride Injection USP (without preservatives) into the reaction vial. 3. Shake the vial gently to bring the lyophilized material into solution 4. If the solution is not clear and free of particulate matter and discoloration on visual inspection it should not be used. The US. Nuclear Regulatory Commission has approved this reagent kit for distribution to persons licensed to use byproduct material identified in of 10 CFH Part 35, to persons who hold an equivalent license issued by an Agreement State, and, outside the United States, to persons authorized by the appropriate authority.
5 Manufactured By: Squibb Diagnostics Princeton, NJ For Medi-Physics, Inc N. Ridge Avenue, Arlington Heights, Illinois Printed In USA Revised November 1990
TECHNESCAN PYP- technetium tc 99m pyrophos phate injection, powder, lyophilized, for solution Mallinckrodt Inc TechneScan PYP
TECHNESCAN PYP- technetium tc 99m pyrophos phate injection, powder, lyophilized, for solution Mallinckrodt Inc. ---------- TechneScan PYP Kit for the Preparation of Technetium Tc 99m Pyrophos phate Injection
More informationTechnescan MAG3. NAME OF THE MEDICINE Technescan MAG3 Kit for the Preparation of Technetium ( 99m Tc) Mertiatide.
Technescan MAG3 NAME OF THE MEDICINE Technescan MAG3 Kit for the Preparation of Technetium ( 99m Tc) Mertiatide. DESCRIPTION Technescan MAG3 is a kit for the preparation of technetium ( 99m Tc) mertiatide,
More informationS U M M AR Y O F P R O D U C T C H AR AC T E R I S T I C S
S U M M AR Y O F P R O D U C T C H AR AC T E R I S T I C S 1 NAME OF THE MEDICINAL PRODUCT Technescan DMSA 1.2 mg kit for radiopharmaceutical preparation 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each
More informationSUMMARY OF PRODUCT CHARACTERISTICS (PHYTATE) mg. Quantity per vial Function. Tc-Technephyte GBq information
CMR Group of Companies info@isotope-cmr.com www.isotope-cmr.com SUMMARY OF PRODUCT CHARACTERISTICS (PHYTATE) 1. NAME OF THE MEDICINAL PRODUCT Technephyte powder for injection, Technephyte, 99m Tc (PHYTATE)
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. TRADE NAME OF THE MEDICINAL PRODUCT TECEOS Kit for the preparation of Technetium[ 99m Tc]3,3-diphosphono-1,2-propanedicarboxylic acid (DPD) injection. 2. QUALITATIVE
More informationSUMMARY OF PRODUCT CHARACTERISTICS
RENOCIS Kit for the preparation of technetium [ 99m Tc] succimer injection SUMMARY OF PRODUCT CHARACTERISTICS T1200nF 08/2008 CIS bio international, member of IBA group 1. NAME OF THE MEDICINAL PRODUCT
More informationContra-indications Myoview is contraindicated in pregnancy and in patients with known hypersensitivity to tetrofosmin or any of the excipients.
MYOVIEW (Kit for the preparation of 99mTc-tetrofosmin) Presentation Each vial contains 230 micrograms tetrofosmin (active ingredient), 0.03 mg stannous chloride dihydrate, 0.32 mg disodium sulphosalicylate,
More informationPHYSICO-CHEMICAL, BIOLOGICAL OR MICROBIOLOGICAL TESTS OF MEDICINAL PRODUCTS
RADIOPHARMACEUTICALS Guideline Title Radiopharmaceuticals Legislative basis Directives 65/65/EEC, 75/318/EEC as amended, Directive 89/343/EEC Date of first adoption December 1990 Date of entry into June
More informationFORM 5 University of California, Davis Health System Health Physics Office HUMAN RADIATION USE RESEARCH APPLICATION
HUMAN RADIATIN USE RESEARCH APPLICATIN Applications must be received at least 14 days prior to the UCDHS Radiation Committee meeting. When an investigative procedure involves exposure of human subjects
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT YTRACIS radiopharmaceutical precursor, solution. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml of sterile solution contains
More informationSUMMARY OF PRODUCT CHARACTERISTICS
PENTACIS Kit for the preparation of technetium ( 99m Tc) pentetate injection SUMMARY OF PRODUCT CHARACTERISTICS T0600nH (T0600-T0611-T0612-T0617) 08/2008 CIS bio international, member of IBA group 1. NAME
More informationGuideline on core SmPC and Package Leaflet for ( 68 Ge/ 68 Ga) generator
1 2 3 26 May 2016 EMA/CHMP/337681/2016 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 Guideline on core SmPC and Package Leaflet for ( 68 Ge/ 68 Ga) generator Draft Draft agreed by Radiopharmaceutical
More informationGuideline on core SmPC and Package Leaflet for ( 68 Ge/ 68 Ga) generator
20 July 2017 EMA/CHMP/337681/2016 Committee for Medicinal Products for Human Use (CHMP) Guideline on core SmPC and Package Leaflet for ( 68 Ge/ 68 Ga) generator Draft agreed by Radiopharmaceutical Drafting
More informationMATERIAL SAFETY DATA SHEET DRAXIMAGE DTPA MATERIAL SAFETY DATA SHEET. Kit for the Preparation of Technetium Tc99m Pentetate Injection
MATERIAL SAFETY DATA SHEET Kit for the Preparation of Technetium Tc99m Pentetate Injection SECTION 1. CHEMICAL PRODUCT & COMPANY IDENTIFICATION Product Name: Kit, + Kit Product Number: 500170, 500520,
More informationSUMMARY OF PRODUCT CHARACTERISTICS
1 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT NANOCOLL 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Human albumin colloidal particles 500 micrograms/vial. At least 95% of human albumin
More informationMaking bone inflammation/infection simpler to detect Scintimun 1mg
Making bone inflammation/infection simpler to detect Scintimun 1mg High confidence in your diagnostic Whole IgG1 antibody offering high specificity of inflammation/ infection process Specific binding to
More information2014 Meeting of Mid-Atlantic States Radiation Control Programs
2014 Meeting of Mid-Atlantic States Radiation Control Programs Brian Cherundolo, BS, RT(R), CNMT Sr. Clinical Applicants Specialist Bracco Diagnostics Inc. Objectives Describe CardioGen-82 Indication and
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER RENOCIS. Kit for the preparation of technetium ( 99m Tc) succimer injection Dimercaptosuccinic acid (DMSA)
PACKAGE LEAFLET: INFORMATION FOR THE USER RENOCIS Kit for the preparation of technetium ( 99m Tc) succimer injection Dimercaptosuccinic acid (DMSA) Read all of this leaflet carefully before you are given
More informationMaterial Safety Data Sheet
Material Safety Data Sheet Kit for the preparation of Technetium Tc99m Medronate for Injection ISSUE DATE: 20-Jun-08 ORIGINATOR: P.E. Buck REVIEWER: Lars Waldmann CHEMICAL PRODUCT/COMPANY IDENTIFICATION
More informationSafety Data Sheet 1. IDENTIFICATION 2. HAZARD IDENTIFICATION 3. COMPOSITION/INFORMATION ON INGREDIENTS
Safety Data Sheet 1. IDENTIFICATION Product Name: DRAXIMAGE MAA Kit for the Preparation of Technetium Tc 99m Macro Aggregated Albumin Injection Product Number: 500150, 500500 Recommended Use: Diagnostic
More informationMATERIAL SAFETY DATA SHEET
GE Healthcare Indium Oxine (Indium-111 Oxyquinoline ) MATERIAL SAFETY DATA SHEET 1. CHEMICAL PRODUCT AND COMPANY IDENTIFICATION Product Name: Indium Oxine Product Code: IN.15PA Synonyms: Indium-111 Oxyquinoline
More informationSafety Data Sheet. Medronic Acid (25 mg) % p-aminobenzoic Acid (5 mg) % Stannous Chloride Dihydrate (2.75 mg) %
Safety Data Sheet 1. IDENTIFICATION Product Name: DRAXIMAGE MDP-25 Kit for the Preparation of Technetium Tc 99m Medronate Injection Product Number: 500661 Recommended Use: Diagnostic Medical Agent. Diagnostic
More informationMATERIAL SAFETY DATA SHEET SECTION 1. CHEMICAL PRODUCT AND COMPANY IDENTIFICATION SECTION 2. COMPOSITION, INFORMATION ON INGREDIENTS
MATERIAL SAFETY DATA SHEET INDIUM In 111 CHLORIDE STERILE SOLUTION SECTION 1. CHEMICAL PRODUCT AND COMPANY IDENTIFICATION Product Name: Indium In 111 Chloride Sterile Solution Synonyms: In 111 Chloride
More informationDRAXIMAGE MDP - 25 Kit for the Preparation of Technetium Tc 99m Medronate Injection
MATERIAL SAFETY DATA SHEET DRAXIMAGE MDP - 25 Kit for the Preparation of Technetium Tc 99m Medronate Injection Section 1. Product and Company Identification Date Published: September 2009 Date Revised:
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Scintimun 1 mg kit for radiopharmaceutical preparation 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial of Scintimun contains
More informationMATERIAL SAFETY DATA SHEET SECTION 1. CHEMICAL PRODUCT AND COMPANY IDENTIFICATION SECTION 2. COMPOSITION, INFORMATION ON INGREDIENTS
MATERIAL SAFETY DATA SHEET SECTION 1. CHEMICAL PRODUCT AND COMPANY IDENTIFICATION Product Name: Thallous Chloride TI 201 Injection Synonyms: Thallium Chloride, Thallium-201 Manufacturer: Mallinckrodt,
More information**MATERIAL SAFETY DATA SHEET**
Date Issued: August 19, 2009 Version: 5.0 Supersedes: August 8, 2006 Page 1 of 5 Section 1 Product and Company Identification Product Name: Herceptin Chemical Name: Anti-p185 HER2 Chemical Family: High
More informationSECTION 1: CHEMICAL PRODUCT AND COMPANY IDENTIFICATION
HDR#### CHOLETEC KIT MATERIAL SAFETY DATA SHEET December 22, 2000 Page 1 of 7 The author of this Material Safety Data Sheet (MSDS) is Bracco Diagnostics Inc. This MSDS is generated and/or distributed by
More informationSUMMARY OF PRODUCT CHARACTERISTICS. for. Galliapharm, radionuclide generator
Date 15 September 2014 SUMMARY OF PRODUCT CHARACTERISTICS for Galliapharm, radionuclide generator This medicinal product is subject to additional monitoring. This will allow quick identification of new
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Cuprymina 925 MBq/mL radiopharmaceutical precursor, solution 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of solution
More informationSUMMARY OF PRODUCT CHARACTERISTICS. for
SUMMARY OF PRODUCT CHARACTERISTICS for Galli Ad, 0.74-1.85 GBq, radionuclide generator 1. NAME OF THE MEDICINAL PRODUCT Galli Ad, 0.74-1.85 GBq, radionuclide generator 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
More informationGuideline on core SmPC for human fibrinogen products
23 July 2015 EMA/CHMP/BPWP/691754/2013 Rev 1 Committee for Medicinal Products for Human Use (CHMP) Draft Agreed by Blood Products Working Party 27 November 2013 Adoption by CHMP for release for consultation
More informationUltra-Technekow FM Mo-99/Tc-99m generator. Product Information
Ultra-Technekow FM Mo-99/Tc-99m generator Product Information Contents Why choose Ultra-Technekow FM? How to use our Ultra-Technekow FM generator Variable elution Accessories Vials Shields Secondary safes
More informationPRINCIPLES OF OPERATION
A dose calibrators is an integral part of any nuclear medicine department. This tutorial focuses on the main principles of operation and all of the issues related to quality control testing of this equipment;
More informationMSDS: IC Green Sterile Indocyanine Green, USP
Material Safety Data Sheet Manufacturer: Akorn Incorporated 150 S. Wyckles Road Decatur, IL 62522 Telephone: 1 800 932 5676 Email: customer.service@akorn.com Section 1 IDENTIFICATION TRADE NAME: IC Green
More informationin94070.txt at Page 1 of 5 2/24/00
in94070.txt at www.nrc.gov Page 1 of 5 UNITED STATES NUCLEAR REGULATORY COMMISSION OFFICE OF NUCLEAR MATERIAL SAFETY AND SAFEGUARDS WASHINGTON, D.C. 20555 NRC INFORMATION NOTICE 94-70: ISSUES ASSOCIATED
More informationRiastap 1 g Powder for solution for injection / infusion Human fibrinogen
Package Leaflet: Information for the user Riastap 1 g Powder for solution for injection / infusion Human fibrinogen Read all of this leaflet carefully before you start using this medicine because it contains
More informationCOMMISSION DECISION of 18/05/98 amending the marketing authorization for the medicinal product for human use. Only the Dutch text is authentic
COMMISSION DECISION of 18/05/98 amending the marketing authorization for the medicinal product for human use "CEREZYME - imiglucerase" Only the Dutch text is authentic THE COMMISSION OF THE EUROPEAN COMMUNITIES,
More informationNuclear Pharmacy. Jim Velez Director, Nuclear Pharmacy (206) (206) Pager
Jim Velez Director, Nuclear Pharmacy (206) 598-3396 (206) 994-8880 Pager jvelez@uw.edu 1 Chapter One Radiopharmaceuticals 1 Radionuclides, Radiochemicals & Radiopharmaceuticals Carrier-free (stable atoms)
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Quadramet 1.3 GBq/mL solution for injection. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of solution contains 1.3 GBq
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Lipactin gel 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 g of gel contains: Heparin sodium..175 IU Zinc sulphate heptahydrate 5 mg
More information2 / 1. SUMMARY public, should be well documented, and should be reviewed on a regular basis to determine whether it continues to meet the operational
1. Summary This Report is concerned with the protection of individuals who may be exposed to radiation emitted by x-ray equipment and both sealed and unsealed radioactive sources in the practice of veterinary
More informationTHE ibritumomab tiuxetan regimen requires
Logistics of Radioimmunotherapy With Yttrium 90 Ibritumomab Tiuxetan (Zevalin) A. Michael Zimmer Radioimmunotherapy is a promising new therapeutic option for the treatment of B-cell non-hodgkin s lymphoma.
More informationRiaSTAP NAME OF THE MEDICINE DESCRIPTION PHARMACOLOGY. Pharmacokinetics. New Zealand Data Sheet. Human fibrinogen, powder for injection.
Page 1 of 12 New Zealand Data Sheet RiaSTAP NAME OF THE MEDICINE Human fibrinogen, powder for injection. DESCRIPTION RiaSTAP is a freeze-dried fibrinogen (coagulation factor I) concentrate derived from
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationUS Regulatory Requirements: Clinical & Clinical Research Production, SPECT & PET Radiopharmaceuticals (RPs)
US Regulatory Requirements: Clinical & Clinical Research Production, SPECT & PET Radiopharmaceuticals (RPs) 20 th International Symposium Radiopharmaceutical Sciences Jeju, Korea Pre-Symposium Workshop
More informationAntidotum Thallii-Heyl
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT 500 mg hard capsules Active pharmaceutical ingredient: Ferric hexacyanoferrate(ii) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 hard
More informationMaterial Safety Data Sheet
Material Safety Data Sheet --------------------- MEBROFENIN ISSUE DATE: 28-Apr-08 ORIGINATOR: P.E. Buck REVIEWER: Lars Waldmann -------------------- CHEMICAL PRODUCT/COMPANY IDENTIFICATION Material Identification
More informationThe RSV season usually runs from October to March each year, whilst the pre-season is typically defined as the months between April and September.
The RSV season usually runs from October to March each year, whilst the pre-season is typically defined as the months between April and September. A multi-disciplinary team (MDT) meeting at the end of
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Yttriga radiopharmaceutical precursor, solution. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml sterile solution contains
More informationSAFETY DATA SHEET SECTION 1: PRODUCT AND COMPANY IDENTIFICATION
SAFETY DATA SHEET SECTION 1: PRODUCT AND COMPANY IDENTIFICATION PRODUCT NAME: Gallium Citrate Ga-67 Injection Version 3.1 11/4/2015 Product Uses This material is used as a radioactive tracer. It is a radioactive
More informationDetermination of 99 Mo contamination in 99m Tc elute obtained from 99 Mo / 99m Tc- generator
Determination of 99 Mo contamination in 99m Tc elute obtained from 99 Mo / 99m Tc- generator M. Momennezhad, S.R. Zakavi *, R. Sadeghi Iran. J. Radiat. Res., 2010; 8 (1): 31-35 Nuclear Medicine Research
More informationKOGENATE FS BAYER MIDDLE EAST
08-15 KOGENATE FS BAYER MIDDLE EAST Formulated with Sucrose DESCRIPTION is a sterile, stable, purified, nonpyrogenic, dried concentrate that has been manufactured using recombinant DNA technology. Kogenate
More informationComplies with the monograph for Parenteral Preparations and with that for Radiopharmaceuticals.
January 2009 THALLOUS ( 201 Tl) CHLORIDE INJECTION: Final text for addition to The International Pharmacopoeia (January 2009) This monograph was adopted at the Forty-third WHO Expert Committee on Specifications
More informationMATERIAL SAFETY DATA SHEET
Page 1 of 5 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222 Emergency telephone
More informationSAMPLE PROCEDURE , 11/07
SAMPLE PROCEDURE This Sample Procedure is not intended as a substitute for your facility s Procedure Manual or reagent labeling, but rather as a model for your use in customizing for your laboratory s
More informationTHALLOUS ( 201 Tl) CHLORIDE INJECTION: Revised Final text for addition to The International Pharmacopoeia (January September 2009)
September 2009 RESTRICTED THALLOUS ( 201 Tl) CHLORIDE INJECTION: Revised Final text for addition to The International Pharmacopoeia (January September 2009) [Note from the Secretariat: This monograph was
More informationPackage leaflet: Information for the patient. Ceftazidim Sandoz, 2.0 g, powder for solution for injection
Package leaflet: Information for the patient Ceftazidim Sandoz, 500 mg, powder for solution for injection Ceftazidim Sandoz, 1.0 g, powder for solution for injection Ceftazidim Sandoz, 2.0 g, powder for
More informationFor In Vitro Diagnostic Use
SYNCHRON System(s) Chemistry Information Sheet Lactate Dehydrogenase REF 442660 For In Vitro Diagnostic Use ANNUAL REVIEW Reviewed by: Date Reviewed by: Date PRINCIPLE INTENDED USE reagent, when used in
More informationFLORIDA HOSPITAL DIAGNOSTIC RADIOLOGY RESIDENCY PROGRAM PHYSICS GOALS AND OBJECTIVES
FLORIDA HOSPITAL DIAGNOSTIC RADIOLOGY RESIDENCY PROGRAM PHYSICS GOALS AND OBJECTIVES Goals and objectives are based on recommendations and requirements from the AAPM, RSNA, NRC, FL DOH, and ACGME Module
More informationTHE INTERNATIONAL PHARMACOPOEIA
June 2013 RESTRICTED 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 THE INTERNATIONAL PHARMACOPOEIA RADIOPHARMACEUTICALS:
More informationLatest Developments in USP Monographs and the Compounding of Sterile Radiopharmaceuticals. Jim Ponto, MS, RPh, BCNP
Latest Developments in USP Monographs and the Compounding of Sterile Radiopharmaceuticals Jim Ponto, MS, RPh, BCNP Disclosures Volunteer member on several USP Expert Committees and Expert Panels associated
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationTECENTRIQ Vials (1,200 mg/20 ml)
Safety Data Sheet TECENTRIQ Vials (1,200 mg/20 ml) SECTION 1: Identification of the substance/mixture and of the company/undertaking 1.1. Product identifier Product name Product code Synonyms TECENTRIQ
More informationTypes of Radiation Units
RADIATION UNITS Types of Radiation Units Exposure in air - amount of ionization produced by or radiation in air. Unit - (R) or / (c/kg) Absorbed Dose energy transfer of / (unit of energy) of any. Used
More informationLatest USP Initiatives: Monographs, General Chapters, and Compounding
Latest USP Initiatives: Monographs, General Chapters, and Compounding Jim Ponto, MS, RPh, BCNP Disclosures Volunteer member on several USP Expert Committees and Expert Panels associated with radiopharmaceutical
More informationA main application of tungsten alloy products, tungsten alloy radiation containers are widely applied in medical and nuclear industries.
Tungsten Alloy Radiation Container Tungsten alloy is used in many radiation-shielding applications including industrial, nuclear and medical. Because of its high density and high atomic number, is an effective
More informationTHROMBIN-JMI (Thrombin, Topical (Bovine) U.S.P.), Solution for topical use Initial U.S. Approval: 1986
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use THROMBIN-JMI safely and effectively. See full prescribing information for THROMBIN-JMI. THROMBIN-JMI
More informationBrachytherapy Practice Problems EXTRA
Brachytherapy Practice Problems EXTRA 1. 100 mci decays to 12.5 mci in days, if the half-life is 17d. a. 170 b. 136 c. 85 d. 51 e. 25 2. A radionuclide has a half-life of 74 d. The activity after 370 days
More informationMIIG INJECTABLE Graft The following languages are included in this packet:
MIIG INJECTABLE Graft 128801-10 The following languages are included in this packet: English (en) Deutsch (de) Nederlands (nl) Français (fr) Español (es) Italiano (it) Português (pt) 中文 - Chinese (sch)
More informationMATERIAL SAFETY DATA SHEET
Page 1 of 6 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222 Emergency telephone
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 3 1. NAME OF THE MEDICINAL PRODUCT INDIMACIS 125 Kit for the preparation of the monoclonal antibody Igovomab 111 In infusion. 2. QUALITATIVE AND QUANTITATIVE
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Cerezyme 200 U Powder for solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial of Cerezyme contains
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 4 1. NAME OF THE MEDICINAL PRODUCT BeneFIX 2. QUALITATIVE AND QUANTITATIVE COMPOSITION BeneFIX, recombinant coagulation factor IX, is prepared in lyophilised
More informationPublic Assessment Report. Scientific discussion. Tranexaminezuur Sandoz 100 mg/ml, solution for injection. (tranexamic acid) NL/H/3153/001/DC
- C Public Assessment Report Scientific discussion Tranexaminezuur Sandoz 100 mg/ml, solution for injection (tranexamic acid) NL/H/3153/001/DC Date: 18 March 2015 This module reflects the scientific discussion
More informationcalculate your cost per head with calculate your cost per head with your current product Cattle Weight lb. Bottle Cost $ Bottle Size ml Cost per ml $ Dose Size ml* Cost $ per head Cattle Weight lb. Bottle
More informationSYNAGIS (palivizumab) injection, for intramuscular use Initial U.S. Approval: 1998
US-10672 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SYNAGIS safely and effectively. See full prescribing information for SYNAGIS. SYNAGIS (palivizumab)
More informationInitial Dose 10,000 units Every 4 to 6 hours 5,000 to 10,000 units. Intermittent IV injection
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use HEPARIN SODIUM IN 0.45% SODIUM CHLORIDE INJECTION safely and effectively. See full prescribing information
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) CORE SPC FOR HUMAN PLASMA DERIVED ANTITHROMBIN
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 17 January 2002 CPMP/BPWG/3226/99 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) CORE SPC
More informationRadiation Safety Policy & Procedures
Radiation Safety Policy & Procedures Emergency Numbers RADIATION SAFETY OFFICER, RAMIN VAKILI... FIRE, POLICE, AND AMBULANCE...- CAMPUSE SECURITY... TABLE OF CONTENTS. PREAMBLE.... SCOPE.... POLICY....
More informationDraft Guidelines for Radiopharmacy
Draft Guidelines for Radiopharmacy In the nuclear medicine laboratories (radiopharmacies) of nuclear medicine clinics in European hospitals, quality assurance varies from non-existent to good manufacturing
More informationRePlay Hemostasis Clip
RePlay Hemostasis Clip Instructions for use. Read carefully prior to use. Caution: Federal (U.S.A.) Law restricts this device to sale by or on the order of a physician. Diversatek Healthcare Corporate
More informationGuidance for Type II variations involving revision of the SPC sections 4.6, 5.3 and 6.6
Federal Agency for Medicines and Health Products Guidance for Type II variations involving revision of the SPC sections 4.6, 5.3 and 6.6 Introduction Taking into account the recurrent similar remarks that
More informationDoxorubicin Hydrochloride Liposome Injection
Doxorubicin Hydrochloride Liposome Injection SECTION 1. Supplier of Data COMPANY AND MATERIAL IDENTIFICATION Getwell Pharmaceuticals 474, Udyog Vihar, Phase-V, Gurgaon - 122 016, Haryana, INDIA In case
More informationRadioactive Substances Act 1993 The Environmental Permitting (England and Wales) (Amendment) Regulations 2011
Exemption guidance Medical and veterinary uses of radioactive sources Version 1 Radioactive Substances Act 1993 The Environmental Permitting (England and Wales) (Amendment) Regulations 2011 1 General questions
More informationElemental Metals and Toxic Effects. Heavy Metals
Elemental Metals and Toxic Effects Many communities may have high levels of toxic metals in their drinking water, particularly those served by from private wells, because of contamination or as a result
More informationRECOMBINATE. [Antihemophilic Factor (Recombinant)] DESCRIPTION. Lyophilized Powder for Reconstitution for injection
RECOMBINATE [Antihemophilic Factor (Recombinant)] Lyophilized Powder for Reconstitution for injection Reconstitute with 5 ml of Sterile Water for Injection using BAXJECT II DESCRIPTION RECOMBINATE [Antihemophilic
More informationCopper: Essential for Human Health
BIOLOGY Copper: Essential for Human Health 14-16 YEARS Copper is an essential trace element vital to the health of all living organisms. Although the amount of copper found in the human body (50 120 milligrams
More information1. Executive Summary
1. Executive Summary The purpose of this Report is to provide guidance to those who may be called to respond to radionuclide contamination incidents. Such incidents may range from situations in which one
More informationDisclaimer statement. International Standards IAEA- US Canada. How do regulatory standards work internationally? How standards evolve.
International Standards IAEA- US Canada August 4, 2011 American Association of Physicists in Medicine Vancouver, British Columbia, Canada Orhan H Suleiman MS PhD, FAAPM Senior Science Policy Adviser Office
More informationInstructions for Use Reprocessed Coronary Sinus Diagnostic Electrophysiology Catheter
Reprocessed by Instructions for Use Reprocessed Coronary Sinus Diagnostic Electrophysiology Catheter Reprocessed Device for Single Use STERILE Explanation of Symbols Federal Law in the USA restricts this
More informationFluoroscopy Credentialing Training Program for Non-Radiologist Physicians. Department of Radiology
Fluoroscopy Credentialing Training Program for Non-Radiologist Physicians Department of Radiology Why Physician Credentialing? FDA. That all facilities assure appropriate credentials and training for physicians
More informationPackage leaflet: Information for the user. Synagis 100 mg/ml solution for injection Active substance: palivizumab
Package leaflet: Information for the user Synagis 100 mg/ml solution for injection Active substance: palivizumab Read all of this leaflet carefully before your child is given this medicine because it contains
More informationRITUXAN(R) Vials (100 mg/10 ml)
Safety Data Sheet RITUXAN(R) Vials (100 mg/10 ml) SECTION 1: Identification of the substance/mixture and of the company/undertaking 1.1. Product identifier Product name Product code Synonyms RITUXAN(R)
More informationAn Investigation To Dose Calculation In Gilan_Iran Industrial Radiography Accident By Using MCNP
18th World Conference on Nondestructive Testing, 16-20 April 2012, Durban, South Africa An Investigation To Dose Calculation In Gilan_Iran Industrial Radiography Accident By Using MCNP Jalil ROUZITALAB
More informationSAFETY DATA SHEET. Non-hazardous in accordance with international standards for workplace safety
Section 1: Identification Product information Product Name Active substance Intended Uses Company Details SAFETY DATA SHEET Torsemide Tablets 5 mg, 10 mg, 20 mg and 100 mg Torsemide Torsemide Tablet is
More informationMATERIAL SAFETY DATA SHEET
Page 1 of 6 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222 Emergency telephone
More informationMATERIAL SAFETY DATA SHEET
Page 1 of 7 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222 Emergency telephone
More information